Ardelyx (ARDX): RA Capital Management Boosts Stake to 7.7%

Peter Kolchinsky‘s RA Capital Management has stepped up its interest in Ardelyx Inc. (NASDAQ:ARDX). As reported in a recent filing with the Securities and Exchange Commission, the fund now holds 3.46 million shares of the stock, plus warrants to acquire an additional 168,225 shares, giving it economic exposure to 7.7% of Ardelyx’s common stock. At the end of March, RA Capital reportedly held 2.3 million shares.

Founded in 2007, Ardelyx Inc. (NASDAQ:ARDX) engages in the research and development of minimally-systemic therapeutics for the treatment of gastrointestinal and cardio-renal diseases. Tenapanor, the company’s top candidate, is currently undergoing Phase 3 trials and has so far demonstrated efficiency in reducing the absorption of dietary sodium and phosphorus, which are key factors in some kidney diseases. The first results from the trials are expected in 2017. The recently agreed-upon takeover of Relypsa Inc (NASDAQ:RLYP) by Galenica has sparked speculation that Ardelyx might be next in line for a takeover, as Relypsa’s top drug, Veltassa, has properties similar to those of Ardelyx’s candidates.

BPMC

At the end of the first quarter, approximately 17% of Ardelyx Inc. (NASDAQ:ARDX)’s common stock was held by nine of the funds tracked by Insider Monkey, up from seven long positions registered three months earlier. Bihua Chen‘s Cormorant Asset Management was also invested in this stock, having indicated ownership of 1.48 million shares of it in its latest 13F filing. James E. Flynn‘s Deerfield Management established a fresh position in the stock during the first quarter, having amassed 275,000 Ardelyx shares by the end of March.

Follow Ardelyx Inc. (NASDAQ:ARDX)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
RA Capital Management 0 3,625,943 0 3,625,943 3,625,943 7.7%
Peter Kolchinsky 0 3,625,943 0 3,625,943 3,625,943 7.7%
RA Capital Healthcare Fund 0 2,451,968 0 2,451,968 2,451,968 5.2%

Follow Peter Kolchinsky's RA Capital Management

Page 1 of 7 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of
1934

 

(Amendment No. __)*


ARDELYX, INC.

 (Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

039697107

(CUSIP Number)

 

July 18, 2016

(Date of Event Which Requires Filing of
this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Page 2 of 7 – SEC Filing

CUSIP No. 039697107 13G
1.

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

 

RA Capital Management, LLC           

2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
 
3. SEC Use Only
 
4. Citizenship or Place of Organization Massachusetts
 
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power 0
 
6. Shared Voting Power 3,625,943
 
7. Sole Dispositive Power 0
 
8. Shared Dispositive Power 3,625,943

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

3,625,943 

10.

Check if the Aggregate Amount in Row (9) Excludes                         ¨

Certain Shares (See Instructions)

11.

Percent of Class Represented by Amount in Row (9)

 

7.7%1

12.

Type of Reporting Person (See Instructions)

IA

1 The reporting person is the beneficial owner of
3,457,718 shares of Common Stock, as well as warrants to acquire 168,225 shares of Common Stock, which together would constitute
approximately 7.7% of the issuer’s Common Stock if the warrants were exercised in full, following the issuance of 168,225
shares of Common Stock in respect of the fully-exercised warrants. The percentage calculation assumes that there are currently
47,230,378 outstanding shares of the Issuer, based on the Issuer’s 10-Q as filed with the Securities and Exchange Commission
(“SEC”) on May 9, 2016 and the Issuer’s 8-K as filed with the SEC on July 20, 2016.

Follow Ardelyx Inc. (NASDAQ:ARDX)

Page 3 of 7 – SEC Filing

CUSIP No. 039697107 13G
  1.

Names
of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Peter Kolchinsky           

2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
       
3. SEC Use Only
  4. Citizenship
or Place of Organization
United States
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power 0

 

6. Shared Voting Power 3,625,943

 

7. Sole Dispositive Power 0

 

8. Shared Dispositive Power 3,625,943

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

3,625,943 

10.

Check if the Aggregate
Amount in Row (9) Excludes                         ¨

Certain Shares (See Instructions)

11.

Percent of Class Represented by Amount in Row (9)

7.7%2

12.

Type of Reporting Person (See Instructions)

 

IN 

2 The reporting person is the beneficial owner of
3,457,718 shares of Common Stock, as well as warrants to acquire 168,225 shares of Common Stock, which together would constitute
approximately 7.7% of the issuer’s Common Stock if the warrants were exercised in full, following the issuance of 168,225
shares of Common Stock in respect of the fully-exercised warrants. The percentage calculation assumes that there are currently
47,230,378 outstanding shares of the Issuer, based on the Issuer’s 10-Q as filed with the SEC on May 9, 2016 and the Issuer’s
8-K as filed with the SEC on July 20, 2016.

Follow Ardelyx Inc. (NASDAQ:ARDX)

Page 4 of 7 – SEC Filing

CUSIP No. 039697107 13G
1.

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

RA Capital Healthcare Fund, L.P.           

2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3. SEC Use Only
4. Citizenship or Place of Organization Delaware
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power 0  
 
6. Shared Voting Power 2,451,968
7. Sole Dispositive Power 0
8. Shared Dispositive Power 2,451,968

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

2,451,968 

10.

Check if the Aggregate Amount in Row (9) Excludes                         ¨

Certain Shares (See Instructions)

11.

Percent of Class Represented by Amount in Row (9)

5.2%3

12.

Type of Reporting Person (See Instructions)

PN (Limited Partnership)

 

3 The reporting person is the beneficial owner of
2,314,024 shares of Common Stock, as well as warrants to acquire 137,944 shares of Common Stock, which together would constitute
approximately 7.7% of the issuer’s Common Stock if the warrants were exercised in full, following the issuance of 137,944
shares of Common Stock in respect of the fully-exercised warrants. The percentage calculation assumes that there are currently
47,230,378 outstanding shares of the Issuer, based on the Issuer’s 10-Q as filed with the SEC on May 9, 2016 and the Issuer’s
8-K as filed with the SEC on July 20, 2016.

 

Follow Ardelyx Inc. (NASDAQ:ARDX)

Page 5 of 7 – SEC Filing

 

Item 1.

(a)           Name of Issuer: ARDELYX,
INC. (the “Issuer”).

(b)           Address of the Issuer’s Principal Executive
Offices:
34175 Ardenwood Blvd., Suite 200, Fremont, CA 94555.

 

Item 2.

(a)           Name of Person
Filing:
This joint statement on Schedule 13G is being filed by Peter Kolchinsky, RA Capital Management, LLC (“Capital”),
and RA Capital Healthcare Fund, L.P. (the “Fund”). Mr. Kolchinsky, Capital and the Fund are collectively referred to
herein as the “Reporting Persons.” Capital is the general partner of the Fund and serves
as investment adviser for a separately managed account (the “Account”). Mr. Kolchinsky is the manager of Capital. As
the investment adviser to the Fund and the Account, Capital may be deemed a beneficial owner, for purposes of Section 13(d) of
the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer owned by the Fund or the Account.
As the manager of Capital, Mr. Kolchinsky may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities
of the Issuer beneficially owned by Capital. Capital is a registered investment adviser within the meaning of Rule 13d-1(b)(1)(ii)(E)
and Rule 16a-1(a)(v), and Mr. Kolchinsky is a parent or control person of Capital within the meaning of Rule 13d-1(b)(1)(ii)(G)
and Rule 16a-1(a)(1)(vii). Capital and Mr. Kolchinsky disclaim beneficial ownership of the securities reported in this Schedule
13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of
the Act, and neither the filing of the Statement nor the filing of this Amendment shall not be deemed an admission that either
Capital or Mr. Kolchinsky is or was the beneficial owner of such securities for any other purpose
.

(b)           Address of
Principal Business Office:
The principal business office of the Reporting Persons is c/o RA Capital Management, LLC, 20 Park
Plaza, Suite 1200, Boston, MA 02116.

(c)           Citizenship:
Capital is a Massachusetts limited liability company. The Fund is a Delaware limited partnership. Mr. Kolchinsky is a United
States citizen.

(d)           Title and Class
of Securities:
Common stock (“Common Stock”) of the Issuer.

(e)           CUSIP Number:
039697107

 

Item 3.           If this statement is filed
pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.           Ownership:

(a)

Amount Beneficially Owned:

See the response(s) to Item 9 on the attached cover
page(s).

(b)

Percent of Class:

See the response(s) to Item 11 on the attached cover page(s).

Follow Ardelyx Inc. (NASDAQ:ARDX)

Page 6 of 7 – SEC Filing

(c) Number of shares as to which such person has:
  (i)

sole power to vote or to direct the vote:

See the response(s) to Item 5 on the attached cover page(s).

 
  (ii)

shared power to vote or to direct the vote

See the response(s) to Item 6 on the attached cover page(s).

 
  (iii)

sole power to dispose or to direct the disposition of

See the response(s) to Item 7 on the attached cover page(s).

 
  (iv)

shared power to dispose or to direct the disposition of

See the response(s) to Item 8 on the attached cover page(s).

Item 5.           Ownership of Five Percent
or Less of a Class:

Not applicable.

 

Item 6.           Ownership
of More than Five Percent on Behalf of Another Person:

Not applicable.

 

Item 7.           Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

 

Item 8.           Identification and Classification
of Members of the Group:

Not applicable.

 

Item 9.           Notice of Dissolution of
Group:

Not applicable.

 

Item 10.         Certification:

By signing below I hereby certify that,
to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of
or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or effect.

Follow Ardelyx Inc. (NASDAQ:ARDX)

Page 7 of 7 – SEC Filing

SIGNATURE

After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 28, 2016
RA CAPITAL MANAGEMENT, LLC
By: /s/ Peter Kolchinsky

Peter Kolchinsky

Authorized Signatory

PETER KOLCHINSKY
/s/ Peter Kolchinsky
RA CAPITAL HEALTHCARE FUND, L.P.
By: RA Capital Management, LLC
Its: General Partner
By: /s/ Peter Kolchinsky

Peter Kolchinsky

Authorized Signatory

Follow Ardelyx Inc. (NASDAQ:ARDX)